Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 84 articles:
HTML format
Text format



Single Articles


    July 2018
  1. HIRANO M, Jimbo K, Ogawa M, Ochi K, et al
    Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2018 Jul 23. pii: 10.1038/s41409-018-0202.
    PubMed     Text format    


    June 2018
  2. FUJI S, Inoue Y, Utsunomiya A, Moriuchi Y, et al
    Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0248.
    PubMed     Text format    


  3. KURUVILLA J, Tzeng CH, Cho SG, Kim SJ, et al
    A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing </=70 kg.
    Bone Marrow Transplant. 2018 Jun 12. pii: 10.1038/s41409-018-0253.
    PubMed     Text format     Abstract available


  4. BEKADJA MA, Talhi S, Amani K, Osmani S, et al
    Outcomes of modified-eam conditioned autologous non-cryopreserved hematopoietic sct for lymphoma. A retrospective single-centre study.
    Bone Marrow Transplant. 2018 Jun 12. pii: 10.1038/s41409-018-0243.
    PubMed     Text format    


  5. ROBINSON SP, Boumendil A, Finel H, Dreger P, et al
    High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
    Bone Marrow Transplant. 2018 Jun 8. pii: 10.1038/s41409-018-0196.
    PubMed     Text format     Abstract available


    May 2018
  6. AVIGDOR A, Shouval R, Jacoby E, Davidson T, et al
    CAR T cells induce a complete response in refractory Burkitt Lymphoma.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0235.
    PubMed     Text format    


  7. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Decision analysis of up-front autologous hematopoietic stem cell transplantation in patients with peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0223.
    PubMed     Text format    


  8. HUBEL K, Ostermann H, Glass B, Noppeney R, et al
    Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0228.
    PubMed     Text format     Abstract available


  9. DREGER P, Michallet M, Bosman P, Dietrich S, et al
    Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone Marrow Transplant. 2018 May 4. pii: 10.1038/s41409-018-0207.
    PubMed     Text format     Abstract available


    April 2018
  10. YANG L, Tan Y, Shi J, Zhao Y, et al
    Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2018 Apr 30. pii: 10.1038/s41409-018-0184.
    PubMed     Text format    


    March 2018
  11. NAITHANI R, Dayal N, Pathak S, Rai R, et al
    Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma.
    Bone Marrow Transplant. 2018 Mar 29. pii: 10.1038/s41409-018-0174.
    PubMed     Text format    


  12. INOUE Y, Fuji S, Tanosaki R, Inamoto Y, et al
    Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.
    Bone Marrow Transplant. 2018 Mar 9. pii: 10.1038/s41409-018-0139.
    PubMed     Text format     Abstract available


    February 2018
  13. AVIVI I, Boumendil A, Finel H, Nagler A, et al
    Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2018 Feb 20. pii: 10.1038/s41409-017-0063.
    PubMed     Text format     Abstract available


  14. MARCHESI F, Capria S, Giannarelli D, Trisolini SM, et al
    BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
    Bone Marrow Transplant. 2018 Feb 13. pii: 10.1038/s41409-018-0120.
    PubMed     Text format    


  15. CASTAGNA L, Boubdallah R, Furst S, Coso D, et al
    Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.
    Bone Marrow Transplant. 2018;53:234.
    PubMed     Text format     Abstract available


    January 2018
  16. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-017-0082.
    PubMed     Text format    


  17. JIMENEZ-UBIETO A, Grande C, Caballero D, Yanez L, et al
    Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.
    Bone Marrow Transplant. 2018 Jan 23. pii: 10.1038/s41409-018-0096.
    PubMed     Text format    


  18. LAHOUD OB, Moskowitz AJ, Horwitz SM, Giralt SA, et al
    Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Jan 22. pii: 10.1038/s41409-017-0086.
    PubMed     Text format    


  19. ROBINSON SP, Boumendil A, Finel H, Peggs KS, et al
    Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2018 Jan 15. pii: 10.1038/s41409-017-0067.
    PubMed     Text format     Abstract available


  20. GAUTHIER J, Poire X, Gac AC, Leclerc M, et al
    Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0018.
    PubMed     Text format     Abstract available


    December 2017
  21. FALCONE U, Jiang H, Bashir S, Tsang R, et al
    Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0054.
    PubMed     Text format    


  22. MARIOTTI J, Bramanti S, Devillier R, Furst S, et al
    Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0032.
    PubMed     Text format    


  23. MOHTY M, Azar N, Chabannon C, Le Gouill S, et al
    Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
    Bone Marrow Transplant. 2017 Dec 18. pii: 10.1038/s41409-017-0033.
    PubMed     Text format     Abstract available


    October 2017
  24. JOFFE E, Rosenberg D, Rozovski U, Perry C, et al
    Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma.
    Bone Marrow Transplant. 2017 Oct 16. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  25. KANSAGRA A, Inwards DJ, Ansell SM, Micallef IN, et al
    Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.
    Bone Marrow Transplant. 2017 Oct 16. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  26. RE A, Gini G, Rupolo M, Levis A, et al
    Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  27. GALIENI P, Troiani E, Bigazzi C, Mazzotta S, et al
    Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  28. RIEDELL PA, Bishop MR
    Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    August 2017
  29. FREEMAN AT, Stover AM, Grover NS, Shea TC, et al
    Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    July 2017
  30. DAMLAJ M, Ghazi S, Syed G, Pasha T, et al
    Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jul 10. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    June 2017
  31. KASSAM S, Chernucha E, O'Neill A, Hemmaway C, et al
    High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  32. GIACCONE L, Festuccia M, Zallio F, Sorasio R, et al
    Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    May 2017
  33. BENTO L, Boumendil A, Finel H, Le Gouill S, et al
    Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2017 May 22. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  34. CASTAGNA L, Bramanti S, Devillier R, Sarina B, et al
    Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
    Bone Marrow Transplant. 2017;52:797.
    PubMed     Text format    


    April 2017
  35. SCHORB E, Fox CP, Fritsch K, Isbell L, et al
    High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
    Bone Marrow Transplant. 2017 Apr 24. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  36. EL CHEIKH J, Massoud R, Abudalle I, Haffar B, et al
    Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Apr 10. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  37. YAMASAKI S, Suzuki R, Hatano K, Fukushima K, et al
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  38. GARNIER A, Guillaume T, Peterlin P, Bene MC, et al
    Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    February 2017
  39. BOURLON C, Alamoudi S, Kumar D, Viswabandya A, et al
    A short tale of blood, kidney and brain: BK virus encephalitis in an allogeneic stem cell transplant recipient.
    Bone Marrow Transplant. 2017 Feb 20. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    January 2017
  40. HEGEROVA L, Cao Q, Lazaryan A, McClune BL, et al
    Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era.
    Bone Marrow Transplant. 2017 Jan 30. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  41. DAMAJ G, Cornillon J, Bouabdallah K, Gressin R, et al
    Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
    Bone Marrow Transplant. 2017 Jan 23. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  42. RADFORD J, McKay P, Malladi R, Johnson R, et al
    Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  43. CASTAGNA L, Bramanti S, Devillier R, Sarina B, et al
    Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  44. FAIR C, Shanley R, Rogosheske J, Lazaryan A, et al
    BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  45. FUJIWARA H, Fuji S, Wake A, Kato K, et al
    Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  46. GAUTHIER J, Castagna L, Garnier F, Guillaume T, et al
    Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  47. HAVERKOS BM, Huang Y, Elder P, O'Donnell L, et al
    A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  48. MCDUFFEE E, Aue G, Cook L, Ramos-Delgado C, et al
    Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    December 2016
  49. STENEHJEM JS, Smeland KB, Murbraech K, Holte H, et al
    Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.
    Bone Marrow Transplant. 2016 Dec 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  50. MEISSNER J, Finel H, Dietrich S, Boumendil A, et al
    Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience.
    Bone Marrow Transplant. 2016 Dec 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    November 2016
  51. SHAH N, Rauenzahn S, Veltri L, Wen S, et al
    Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  52. GHEZ D, Fortpied C, Mounier N, Carde P, et al
    First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  53. ROBINSON SP
    Diffuse large B-cell lymphoma: the challenge of relapse after an autologous stem cell transplant.
    Bone Marrow Transplant. 2016 Nov 21. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    October 2016
  54. POLISTENA P, Tran Q, Cirillo M, O'Sullivan M, et al
    Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 Oct 31. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  55. GAUTHIER J, Holmberg L, Wu D, Bensinger W, et al
    Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.
    Bone Marrow Transplant. 2016 Oct 24. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  56. CASTAGNA L, Sarina B, Crocchiolo R, Bramanti S, et al
    Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Oct 17. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    September 2016
  57. BAI L, Peters L, Xia W, Best G, et al
    Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product.
    Bone Marrow Transplant. 2016 Sep 26. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  58. VAN DEN NESTE E, Schmitz N, Mounier N, Gill D, et al
    Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  59. PHILLIPS EH, Hodson A, Hermine O, Bazarbachi A, et al
    Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?
    Bone Marrow Transplant. 2016 Sep 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  60. RAMASWAMI R, Pria AD, Parker K, McCann S, et al
    Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma.
    Bone Marrow Transplant. 2016 Sep 5. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    July 2016
  61. CAGDAS D, Erman B, Hanoglu D, Tavil B, et al
    Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
    Bone Marrow Transplant. 2016 Jul 25. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  62. EHRLICH KB, Miller GE, Scheide T, Baveja S, et al
    Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    June 2016
  63. LINK CS, Mies F, Scheele J, Kramer M, et al
    Long-term follow-up of patients with relapsed or refractory non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    May 2016
  64. KOTHARI J, Foley M, Peggs KS, Mackenzie S, et al
    A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
    Bone Marrow Transplant. 2016 May 23. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  65. TSIRIGOTIS P, Danylesko I, Gkirkas K, Shem-Tov N, et al
    Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 May 16. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  66. GAYOSO J, Balsalobre P, Pascual MJ, Castilla-Llorente C, et al
    Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  67. BEIER R, Sykora KW, Woessmann W, Maecker-Kolhoff B, et al
    Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    April 2016
  68. SINGH AK, Porrata LF, Aljitawi O, Lin T, et al
    Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  69. HONG S, Rybicki L, Abounader DM, Bolwell BJ, et al
    Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  70. TESSOULIN B, Ceballos P, Chevallier P, Blaise D, et al
    Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  71. HOCHBERG J, Harrison L, Morris E, Militano O, et al
    Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 Apr 18. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  72. STAMATOULLAS A, Brice P, Gueye MS, Mareschal S, et al
    Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
    Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    March 2016
  73. VARMA A, Saliba RM, Torres HA, Afrough A, et al
    Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation.
    Bone Marrow Transplant. 2016 Mar 7. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    February 2016
  74. YARED JA, Hardy N, Singh Z, Hajj S, et al
    Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Feb 1. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  75. NELSON AA, Harrington AM, Kroft S, Dahar MA, et al
    Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer.
    Bone Marrow Transplant. 2016;51:300-2.
    PubMed     Text format    


    January 2016
  76. RASHIDI A, Ebadi M, Cashen AF
    Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2016 Jan 4. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    November 2015
  77. ROBINSON SP, Boumendil A, Finel H, Blaise D, et al
    Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2015 Nov 30. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  78. MAMEZ AC, Levy V, Chevallier P, Blaise D, et al
    Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
    Bone Marrow Transplant. 2015 Nov 23. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  79. SELLNER L, Boumendil A, Finel H, Choquet S, et al
    Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
    Bone Marrow Transplant. 2015 Nov 16. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    September 2015
  80. HAIK L, Beylot-Barry M, Vigouroux S, Tabrizi R, et al
    Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2015 Sep 14. doi: 10.1038/bmt.2015.
    PubMed     Text format    


    August 2015
  81. YERUSHALMI R, Shem-Tov N, Danylesko I, Avigdor A, et al
    Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    June 2015
  82. GARCIAZ S, Castagna L, Bouabdallah R, Furst S, et al
    Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.
    Bone Marrow Transplant. 2015;50:865-7.
    PubMed     Text format    


    May 2015
  83. BERGER NA
    A time to stop, a time to start: high-dose chemotherapy in overweight and obese patients.
    Bone Marrow Transplant. 2015;50:617-8.
    PubMed     Text format    


    March 2015
  84. HONG S, Le-Rademacher J, Artz A, McCarthy PL, et al
    Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.
    Bone Marrow Transplant. 2015;50:367-74.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: